Admescope, part of the Symeres family, has provided tailor-made ADME-Tox services to biotech and pharma companies worldwide for over ten years. As the biotech industry continues to expand, so does Admescope and we are delighted to announce a new US-based member of the team, Leah Haydock.
With over 15 years of experience in international business, sales and marketing at companies including Evans Medical, Smith & Nephew and Cynosure, Leah is excited to join the Admescope business development team and put her background in pharmacology to good use. Leah recently spent 10 days at the Admescope facility in Oulu, meeting the scientific team, visiting the labs and learning about our process of providing high-quality scientific and technical data that customers rely on for their decision making. There was also training in traditional Finnish activities such as forest skiing in unbroken snow and cooking sausages over a fire!
The US is just one of the 30 countries serviced by Admescope. Our teams of dedicated and specialized scientists in Finland, Sweden and Netherlands have completed numerous studies in drug metabolism, drug interactions, quantitative bioanalysis, biologics including ADC characterization to AAALAC accredited in vivo PK studies, metabolites in safety testing (MIST) and more.
Admescope is a preclinical contract research organization (CRO) committed to working closely with our customers throughout the whole study process. All studies involve comprehensive study planning, tailoring assays and protocols and interpretation of the results with recommendations for the future. We serve as a true partner and we offer our deep ADME-Tox expertise to assist our clients in their decision making.
“Admescope offers an impressive and broad portfolio of ADME-Tox services, from high-throughput early ADME profiling to tailor-made complex studies. As a resident of Boston, I see almost never-ending construction of new biotech, life science and pharmaceutical buildings from Kendall Sq to Fort Point and know this is such an exciting time for drug discovery. I’m excited to introduce our CRO services locally in Boston and Cambridge and further afield”said Leah.
Leah is especially looking forward to a collaborative working relationship with Bart DeCorte and Chris Teleha who are responsible for business development for Symeres, the parent company of Admescope. ‘We are delighted to have Leah join our organization. Leah’s background nicely compliments our medicinal chemistry and drug development skills and allows us to offer the full spectrum of synthesis and ADME-Tox expertise to our clients.” said Bart DeCorte.
On June 8-9, 2022, Leah will attend the Precision in Drug Discovery and Preclinical Summit in Boston, MA with colleagues Miia Kovalainen, Head of Business Development for Admescope and Russ Thomas, Head of Business Development for Symeres. If you are a biotech or pharma business on the East Coast, we’d love to learn more about your ADME-Tox needs and share how our customer-focused approach can save you time, development costs and reduce late failures. Reach out to set up a meeting today!
